Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing contract, removing an overhang that has weighed on the stock for some time ...

Viking Therapeutics ( VKTX -0.30%) is a promising growth stock with a strong GLP-1 drug candidate in VK2735, which may ...

Gerard Bottino / SOPA Images / LightRocket via Getty Images Viking Holdings shares dropped Tuesday as executives warned of macroeconomic "uncertainties" on the cruise operator's fourth-quarter ...

Viking’s stock fell 12.6% to a low of $24.4 following the announcement, due to some investor chatter indicating that the latest news has made the company a potential acquisition target. “It is very ...

The stock surged more than 120% in one trading session after Viking spoke about VK2735, a candidate that works in the same way as big pharma Eli Lilly's blockbuster drugs Mounjaro and Zepbound.

Both Viking and Roche are attempting to horn in on this market ... The companies plan to sell it both separately and in combination with Roche's CT-388 incretin drug. Image source: Getty Images. Both ...